1560649-16-2

Upstream product

• 542-92-7 cyclopenta-1,3-diene 
• 1208009-37-3 (S)-2-(6-(4,4,5,5-tetramethyl-1,3,2-dioxapentane-2-yl)-1H-benzo[d]imidazole -2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1208007-67-3 (S)-tert-butyl 2-(6-bromo-1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 1561214-03-6 C₃₃H₃₄N₈ 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 1560642-79-6 C₄₃H₅₀N₈O₄ 
• 1560642-78-5 C₂₇H₃₀ClN₅O₂ 
• 19479-86-8 bicyclo<2.2.1>hept-2-ene-2,3-dicarboxylic anhydride 
• 16508-04-6 bicyclo<2,2,1>hept-2-ene-2,3-dicarboxylic acid 
• 17931-56-5 Dimethyl Bicyclo<2.2.1>hept-2-ene-2,3-dicarboxylate 
• 947-57-9 dimethyl bicyclo[2.2.1]hept-2,5-diene-2,3-dicarboxylate 
• 1007882-12-3 (S)-tert-butyl 2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.